

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, its management, as well as financial statements. No public offer of securities is to be made by the Company in the United States.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

US\$200 MILLION 6.9% SENIOR NOTES DUE 2021

UPDATE ON OFFSHORE DEBT RESTRUCTURING

Reference is made to the announcement of the Company dated 6 October 2021 in relation to the proposed offshore debt restructuring (the “**Announcement**”). Unless otherwise defined therein, capitalised terms and expressions used herein shall have the same meaning as defined in the Announcement.

EXTENSION OF THE CONSENT FEE DEADLINE

By 4:00 p.m. (Hong Kong time) on the date of this announcement, Noteholders holding Notes in aggregate principal amount of US\$166,679,000, representing approximately 89.5% by value of the aggregate outstanding principal amount of the Notes (being US\$186,323,000 after cancellation of the Notes repurchased by the Company on market in 2021), have entered into or acceded to the New RSA. In order to encourage more Noteholders to accede to the New RSA and support the Proposed Restructuring and in accordance with the terms of the New RSA, the Company hereby announces the extension of the Consent Fee Deadline from 5:00 p.m. (Hong Kong time) on 20 October 2021 to 8:00 p.m. (Hong Kong time) on 1 December 2021.

Further announcement(s) will be made by the Company to inform the shareholders and potential investors of any material development as and when appropriate.

Shareholders and investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

20 October 2021

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Li Bin; the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.